Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer

Meseure, Didier; Vacher, Sophie; Lallemand, François; Alsibai, Kinan Drak; Hatem, Rana; Chemlali, Walid; André, Nathalie; Koning, Leanne de; Pasmant, Éric; Callens, Céline; Lidereau, Rosette; Morillon, Antonin; Bièche, Ivan

doi:10.1038/bjc.2016.123

Cited by 81 publications

(69 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its superior level in TNBC than in ER positive breast subtype, indicates that MALAT1 is more highly expressed in ER positive cell lines [47]. This ER-related expression has been supported both in full-length MALAT1 and an alternatively spliced variant of MALAT1 [48, 49]. By interacting with polycomb 2 protein, MALAT1 could mediate gene activation by relocating growth-related genes as well [50].…”

Section: Malat1mentioning

confidence: 99%

Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Xiong

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs), which occupy nearly 98% of genome, have crucial roles in cancer development, including breast cancer. Breast cancer is a disease with high incidence. Despite of recent progress in understanding the molecular mechanisms and combined therapy strategies, the functions and mechanisms of lncRNAs in breast cancer remains unclear. This review presents the currently basic knowledge and research approaches of lncRNAs. We also highlight the latest advances of seven classic lncRNAs and three novel lncRNAs in breast cancer, elucidating their mechanisms and possible therapeutic targets. Additionally, association between lncRNA and specific molecular subtype of breast cancer is reported. Lastly, we briefly delineate the potential roles of lncRNAs in clinical applications as biomarkers and treatment targets.

show abstract

Section: Malat1mentioning

confidence: 99%

Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Xiong

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…UCA1 upregulation and subsequent mTOR activation by UCA1 downregulates tumor‐suppressive miR‐143, which is stated as a potential mechanism (Tuo, Li, & Luo, 2015; Xue, Chen, & Li, 2016). GAS5 functions as a molecular sponge for miR‐21 that leads to increased PTEN expression, which in turn, brings about cell proliferation inhibition and apoptosis (Meseure et al, 2016). Li et al demonstrated that activation of mTOR/Akt signaling blocks GAS5 and attenuates the expression of PTEN, which advocates cancer cell growth and migration.…”

Section: Crosstalk Between Various Signaling Pathways and Lncrnasmentioning

confidence: 99%

Critical roles of long noncoding RNAs in breast cancer

Abolghasemi

Tehrani

Yousefi

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Breast cancer is a major clinical challenge that affects a wide range of the female population and heavily burdens the health system. In the past few decades, attempts have been made to understand the etiology of breast cancer, possible environmental risk factors, and the genetic predispositions, pathogenesis, and molecular aberrations involved in the process. Studies have shown that breast cancer is a heterogeneous entity; each subtype has its specific set of aberrations in different cell signaling pathways, such as Notch, Wnt/β‐catenin, transforming growth factor‐β, and mitogen‐activated protein kinase pathways. One novel group of molecules that have been shown to be inducted in the regulation of multiple cell signaling pathways is the long noncoding RNAs (lncRNAs). These molecules have important implications in the regulation of multiple signaling pathways by interacting with various genes, affecting the transcription process, and finally, playing roles in posttranslational control of these genes. There is growing evidence that lncRNAs are involved in the process of breast cancer formation by effecting the aforementioned signaling pathways, and that this involvement can have significant diagnostic and prognostic values in clinical contexts. The present review aims to elicit the significance of lncRNAs in the regulation of cell signaling pathways, and the resulting changes in cell survival, proliferation, and invasion, which are the hallmarks of breast cancer.

show abstract

“…Many cancer-related genes have been well characterized for both their functions and aberrant expression or splicing in cancers. In a study using a peptidomics approach to search for novel transcript variants in clinical proteomics, Zhang et al identified novel alternative splicing isoform biomarkers of breast cancer [86]. In another report, Venables et al compared alternative splicing profiles of 600 cancer-associated genes between normal and breast cancer samples, and validated 41 alternative splicing events that significantly differed among these two groups of samples.…”

Section: Clinical Application Of Alternative Splicing In Cancer Thmentioning

confidence: 99%

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform

Tian

Shi

et al. 2017

IJMS

View full text Add to dashboard Cite

Alternative pre-mRNA splicing is a crucial process that allows the generation of diversified RNA and protein products from a multi-exon gene. In tumor cells, this mechanism can facilitate cancer development and progression through both creating oncogenic isoforms and reducing the expression of normal or controllable protein species. We recently demonstrated that an alternative cyclin D-binding myb-like transcription factor 1 (DMTF1) pre-mRNA splicing isoform, DMTF1β, is increasingly expressed in breast cancer and promotes mammary tumorigenesis in a transgenic mouse model. Aberrant pre-mRNA splicing is a typical event occurring for many cancer-related functional proteins. In this review, we introduce general aberrant pre-mRNA splicing in cancers and discuss its therapeutic application using our recent discovery of the oncogenic DMTF1 isoform as an example. We also summarize new insights in designing novel targeting strategies of cancer therapies based on the understanding of deregulated pre-mRNA splicing mechanisms.

show abstract

Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer

Abstract: Background: Epigenetic deregulation is considered as a new hallmark of cancer. The long non-coding RNA MALAT1 has been implicated in several cancers; however, its role in breast cancer is still little known.

Cited by 81 publications

References 32 publications

Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication

Critical roles of long noncoding RNAs in breast cancer

From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform

Contact Info

Product

Resources

About